[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635456":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":41,"collaborators":45,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"St Vincent's Hospital, Sydney","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"A qualitative approach with semi-structured interviews.","EXPERIMENTAL","Through purposive sampling, we plan to conduct interviews with men from two groups: those with high-risk BCR PCa but no ADT+\u002F-ARPI experience, and men with ADT+\u002F-ARPI experience who have experienced breast-related side effects from this treatment. To inform an understanding of how perception of breast-related symptoms might inform treatment preferences, it is important to understand perspectives regarding the hypothetical risk of side-effects as well as those based on actual experience.",[13],"Other: Semi-structured Interview",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Semi-structured Interview","this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).",[9],null,[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Kinghorn Cancer Centre","RECRUITING","Sydney","New South Wales","2010","Australia","AU",{"type":30,"coordinates":31},"Point",[32,33],151.20732,-33.86785,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":19,"email":40},"Anthony M Joshua, MBBS PhD","CONTACT","+61293555655","svhs.cancerresearch@svha.org.au",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Anthony Joshua, FRACP","Medical Oncologist",[46],{"name":47,"class":6},"University of Technology, Sydney","100635456","determining-individual-preferences-for-gynecomastia-avoidance-dingo---stage-1-100635456",false,"NCT07552922","Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1","Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Qualitative Stage","DINGO","Inclusion Criteria:\n\n* Men with high-risk BCR PCa but no ADT+\u002F-ARPI experience.\n* Men with ADT+\u002F-ARPI experience who have experienced breast-related side effects from this treatment.\n\nExclusion Criteria:\n\n• Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.","MALE","18 Years",{"count":59,"type":60},24,"ESTIMATED","INTERVENTIONAL",[63],"NA","This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.",[66],"Prostate Cancer (Adenocarcinoma)",[68,69,70,71,72,73],"gynaecomastia","prostate cancer","LHRH","testosterone","breast","estrogen","2026-04-22",{"date":76,"type":77},"2026-04-27","ACTUAL",{"date":79,"type":77},"2025-12-01",{"date":81,"type":60},"2026-11-30",{"name":5,"class":6},1]